Bruker Corporation BRKR recently launched the new X4 POSEIDON, a high-performance 3D X-ray microscope (XRM) using micro-Computed Tomography (microCT). Representing a significant leap in benchtop XRM design and performance, it offers advanced capabilities similar to larger, floor-standing systems to make high-resolution 3D X-ray microscopy accessible for demanding XRM applications.

The X4 POSEIDON is designed for use in industrial applications and scientific research.

BRKR Stock’s Likely Trend Following the News

Since the announcement on Feb. 27, shares of Bruker have lost 7.2%, finishing at $46.87 yesterday. On a promising note, the company fosters innovation, improved productivity and customer success in post-genomic life science molecular and cell biology research. Bruker’s differentiated systems and solutions support research in the fields of preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as clinical microbiology and molecular diagnostics. Hence, we expect the latest development to boost the market sentiment toward BRKR stock.

Bruker has a market capitalization of $7.04 billion. The Zacks Consensus Estimate for the company’s 2025 revenues indicates an increase of 3.9%. In the trailing four quarters, it delivered an earnings beat of 3.7%, on average.

Significance of Bruker’s New XRM

The X4 POSEIDON features a high-end X-ray source that improves 3D resolution by more than an order of magnitude compared to similar instruments. The state-of-the-art system offers a large field-of-view high-efficiency detector, which optionally can be combined with a high-resolution scientific CMOS detector for multi-vision analytical flexibility.

Image Source: Zacks Investment Research

Powered by 3DxSUITE software, the X4 POSEIDON comes with automated protocols, an intuitive and customizable user interface, integrated database and user management and multi-language support. Designed for low maintenance, the system enhances uptime and reduces the cost of ownership. Options are field-upgradable, allowing for cost-effective expansion to meet evolving analytical needs and future innovations.

According to Bruker’s leadership team, the system offers flexibility and performance for fast 3D high-resolution XRM with a large field of view for industrial and materials science research applications in the geosciences, pharmaceutical R&D and QA/QC, composite materials, batteries, renewable energy and microelectronics. With its unmatched image quality, the X4 POSEIDON stands out in its category, making it ideal for performance across life-science applications from bone and dental research to soft tissue imaging and plant and animal biology.

Industry Prospects Favoring Bruker Stock

Per a research report, the high-resolution 3D XRM market was valued at $1.3 billion in 2023 and is expected to grow at a compound annual rate of 8.1% by 2032. The upcoming trends in this market include the development of advanced software algorithms for image processing and analysis, as well as the integration of artificial intelligence (AI) and machine learning capabilities.

More Updates From Bruker

At the 21^st Annual US HUPO Conference last month, Bruker announced significant advances in 4D-Proteomics performance, software and applications for deeper biological insights. These include the novel Athena Ion Processor (AIP) on the timsTOF Ultra 2 system, the launch of DeutEx software for hydrogen-deuterium exchange (HDX-MS) analysis and the new OmniScape 2025b software version. In addition, the company shared advances in immunopeptidomics, ProteoScape and Glycoproteomics software capabilities and AI-enabled TwinScape software.

BRKR Stock Price Performance

In the past three months, Bruker shares have lost 23.7% in value compared with the industry’s 24.3% fall.

BRKR’s Zacks Rank and Key Picks

Bruker currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the broader medical space include Hims & Hers Health HIMS, Inspira Medical Systems INSP and Cardinal Health CAH. Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Estimates for Hims & Hers Health’s 2025 earnings per share have jumped 34.6% to 70 cents in the past 30 days. Shares of the company have surged 186.2% in the past year against the industry’s 11.2% fall. HIMS’ earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 40.4%.

Inspira shares have dipped 2.3% in the past year. Estimates for the company’s 2025 earnings per share have increased 6.4% to $2.16 in the past 30 days. INSP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 332.5%. In the last reported quarter, it posted an earnings surprise of 55.4%.

Estimates for Cardinal Health’s fiscal 2025 earnings per share have increased 14.7% to $7.94 in the past 30 days. Shares of the company have jumped 12.8% in the past year against the industry’s 2.1% fall. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cardinal Health, Inc. (CAH) : Free Stock Analysis Report

Bruker Corporation (BRKR) : Free Stock Analysis Report

Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report

Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research